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Abstract: An expert group of 40 pain specialists from 16 countries performed a first assessment 
of the value of predictors for treatment success with 5% lidocaine-medicated plaster in the man-
agement of cancer pain with neuropathic components and trigeminal neuropathic pain. Results 
were based on the retrospective analysis of 68 case reports (sent in by participants in the 4 weeks 
prior to the conference) and the practical experience of the experts. Lidocaine plaster treatment 
was mostly successful for surgery or chemotherapy-related cancer pain with neuropathic com-
ponents. A dose reduction of systemic pain treatment was observed in at least 50% of all cancer 
pain patients using the plaster as adjunct treatment; the presence of allodynia, hyperalgesia or 
pain quality provided a potential but not definitively clear indication of treatment success. In 
trigeminal neuropathic pain, continuous pain, severe allodynia, hyperalgesia, or postherpetic 
neuralgia or trauma as the cause of orofacial neuropathic pain were perceived as potential pre-
dictors of treatment success with lidocaine plaster. In conclusion, these findings provide a first 
assessment of the likelihood of treatment benefits with 5% lidocaine-medicated plaster in the 
management of cancer pain with neuropathic components and trigeminal  neuropathic pain and 
support conducting large, well-designed multicenter studies.
Keywords: lidocaine plaster, neuropathic pain, cancer pain, trigeminal neuropathic pain, case 
reports
Background
Neuropathic pain that “arises as a direct consequence of a lesion or disease affecting the 
somatosensory system”1,2 is experienced by 6%–8% of adults in the general population.3 
Prevalence can vary according to the underlying condition, eg, approximately 20% of 
patients with long-standing diabetes, and approximately 8% of individuals who suffered 
from shingles are affected.3 The risk is higher in older adults, because the incidence of 
many diseases causing neuropathic pain increases with age.4 Pharmacotherapy remains 
the most important treatment option5 but three-quarters of patients in cross-sectional 
surveys still had moderate to severe pain despite taking medications.6
The topical analgesic 5% lidocaine-medicated plaster (Versatis®; Grünenthal, 
Aachen, Germany) is recommended as first-line treatment for localized peripheral 
neuropathic pain.7,8 The lidocaine plaster has shown good efficacy and tolerability in 
patients with postherpetic neuralgia,9–11 diabetic polyneuropathy,9 and other neuropathic 
pain states.12–15 Pain relief was observed for up to 7 treatment years with daily plaster 
use.16–20 Recently, a decrease in the painful surface area following lidocaine plaster 
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treatment was demonstrated for the first time in a prospective 
clinical study21 and confirmed in surrogate neuropathic pain 
models in healthy volunteers.22
Currently, attempts are underway to supplement the tra-
ditional classification of neuropathic pain (based on disease 
entities, anatomical localization or histological observations) 
by a mechanism- or symptom-based classification.23 The 
efficacy of the lidocaine plaster in different neuropathic pain 
conditions has led to the hypothesis of a common localized 
symptomatology that might provide common predictors 
of treatment success. The availability of positive- and 
negative-outcome predictors for a certain treatment might 
shorten the “trial and error” period in finding a successful 
treatment for a patient, thus providing pain relief and better 
quality of life faster. Previous meetings of pain specialists 
in 2007, 2008, and 2009 focused on potential outcome pre-
dictors for the indications diabetic polyneuropathy (DPN), 
complex regional pain syndrome (CRPS), chronic low back 
pain with neuropathic components, and chronic neuropathic 
pain after surgical and nonsurgical trauma. Based on case 
reports and clinical experience of the participants, presence 
of localized pain, allodynia, hyperalgesia, and superficial 
pain were considered positive predictors for treatment suc-
cess with the lidocaine plaster, whereas the predictive value 
of pain quality differed depending on the indication and 
was considered uncertain. Treatment success was generally 
considered unlikely in the presence of chronic widespread 
pain, deep pain, or numbness.24 The probability of treatment 
success with the lidocaine plaster for cancer pain with neu-
ropathic components and trigeminal neuropathic pain has 
so far been considered mainly on anecdotal evidence. Pain 
specialists experienced in lidocaine plaster treatment of one 
or both pain states therefore discussed possible outcome 
predictors for these two indications at an additional 2-day 
meeting held in 2010.
Cancer pain with neuropathic 
components
Pain is prevalent in cancer patients and considerably impairs 
their quality of life.25 The pain is often experienced at mul-
tiple sites and tends to increase in severity with advancing 
disease. Cancer pain can be nociceptive or neuropathic; 
patients often present with a mixed nociceptive/neuropathic 
type.26,27 The prevalence of neuropathic pain in cancer pain 
has been estimated at between 11.8% and 33%,28–30 but could 
be higher, as patients with mixed pain were not included in 
the neuropathic pain estimate in one study.29 Neuropathic pain 
can arise from nerve compression or direct tumor infiltration 
or can be induced by cancer treatments such as surgery, 
radiotherapy, or chemotherapy.31,32 In some cases, the pain 
is cancer-independent and caused by concomitant disorders. 
Pharmacological management of cancer pain usually fol-
lows the World Health Organization’s analgesic ladder for 
cancer pain relief;33 however, this approach does not take 
into account the special aspects of neuropathic pain. Cancer 
pain is difficult to manage, especially in patients with neuro-
pathic pain components;34 the use of adjuvant analgesics with 
proven efficacy in the management of neuropathic pain8 is 
therefore recommended. So far, lidocaine plaster treatment of 
cancer patients with neuropathic pain has provided analgesic 
efficacy in some cases35,36 but not in others.37
Trigeminal neuropathic pain
Facial pain is a rare but severe condition with an incidence 
rate of 38.7 per 100,000 person years;38 it has a profound 
effect on quality of life.39 Trigeminal neuralgia is the most 
widely recognized neuropathic facial pain, but there are other 
neuropathic pain types that require a different treatment regi-
men.40 Criteria of the International Association for the Study 
of Pain2 or of the International Classification of Headache 
Disorders41 are used for diagnosis and classification, which 
can be challenging because signs and symptoms of differ-
ent pain types can overlap considerably.42,43 Misdiagnosis by 
general practitioners (nonspecialists in this field) can thus be 
substantial.38 One neuropathic pain type is trigeminal neuro-
pathic pain, which needs to be differentiated from trigemi-
nal neuralgia and requires a different treatment approach. 
A comparison of diagnostic criteria for the two pain types is 
listed in a recent publication.39 Trigeminal neuropathic pain 
is described as “aching throbbing” or burning pain around a 
tooth or area of past dental trauma/surgery or facial trauma, 
and is continuous soon after the injury occurred (in contrast to 
trigeminal neuralgia pain, which is described as sudden, brief, 
and extremely painful pain attacks).39 However, some forms 
of trigeminal neuralgia have a more prolonged afterpain, 
which has been termed either atypical trigeminal neuralgia 
or more recently type 2 trigeminal neuralgia.44 Trigeminal 
neuropathic pain can be localized or may radiate, is evoked 
by light touch, and associated with allodynia. Also described 
in the literature is a chronic dental pain called atypical 
odontalgia,45 which may constitute a subtype of trigeminal 
neuropathic pain.40 For pharmacological treatment, it is rec-
ommended to follow the guidelines used for the management 
of neuropathic pain,8 which include tricyclic antidepressants, 
calcium channel blockers (gabapentin and pregabalin), the 
serotonin–norepinephrine reuptake inhibitors duloxetine and 
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venlafaxine, and the 5% lidocaine-medicated plaster.40 To our 
knowledge, use of the lidocaine plaster has so far only been 
described in a retrospective analysis of the management of 
iatrogenic trigeminal nerve injury.46
Meeting details
During a 2-day meeting facilitated by Grünenthal in December 
2010 in Aachen, Germany, pain specialists experienced in the 
use of the 5% lidocaine-medicated plaster treatment for the 
management of cancer pain with neuropathic components and/
or trigeminal neuropathic pain discussed possible predictors 
for a treatment response to the lidocaine plaster. The discus-
sions were based on the retrospective analysis of case reports 
and the practical experience of the participants. Cases were 
discussed, and if there was a lack of agreement on the quality 
of data, they were excluded. Forty pain practitioners from 16 
countries participated. They formed two discussion groups 
for lidocaine plaster use in cancer pain with neuropathic 
components, and one group for use in trigeminal neuropathic 
pain, each moderated by the authors of this paper.
Approximately 4 weeks prior to the meeting, all partici-
pants were asked to contribute case reports for one or both of 
the clinical indications using standardized and anonymized 
forms. This time frame allowed retrospective data analysis, 
but was insufficient for starting treatment in new patients 
for the purpose of data collection, which was not permit-
ted.  During the meeting, it became evident that additional 
information pertaining to the cause of neuropathic pain was 
considered useful for the analysis. Additional questions refer-
ring to the initially supplied case reports were therefore sent 
out to all contributing practitioners shortly after the meeting. 
Overall, the following data were obtained:
•	 Demographic data.
•	 Primary diagnosis (pain indication/cause of pain).
•	 Other relevant diagnoses.
•	 Cause of neuropathic pain; was pain related to the under-
lying condition or was it treatment-induced?
•	 Localization of pain symptoms.
•	 Duration and intensity of pain prior to initiation of treat-
ment with lidocaine plaster.
•	 Physical examination and diagnostic tests.
•	 Presence of clinical symptoms of pain and pain quality 
(hyperalgesia, presence and severity of allodynia, stabbing 
pain, burning pain, shooting pain, other symptoms).
•	 Prior and concomitant medication.
•	 Start of therapy with lidocaine plaster.
•	 Application frequency, number of plasters, and duration 
of treatment.
•	 Clinical Global Impression of Change (CGIC) score 
during treatment with lidocaine plaster (from 1 = very 
much improved to 6 = very much worse).
•	 Occurrence of adverse events.
•	 Conclusions of the practitioner.
The presence of hyperalgesia (increased pain sensitiv-
ity in response to nociceptive stimuli) and allodynia (pain 
response to nonnociceptive stimuli) was confirmed by the 
treating physician using diagnostic tools of his/her choice. 
Allodynia severity was rated on a scale from 0 = no pain 
or discomfort to touch, 1 = uncomfortable, but tolerable to 
touch, 2 = painful, to 3 = extremely painful, patient cannot 
stand touching.
Sixty-eight case reports were submitted by 18 pain prac-
titioners from the following countries: Belgium (2), Czech 
Republic (1), France (3), Germany (2), Poland (2), Portugal 
(3), Slovakia (1), Slovenia (1), Spain (1), The Netherlands 
(1), and the United Kingdom (1). All reports were displayed 
during the discussion sessions and tabulated according to 
indication. The original report forms were also available for 
perusal at each session. Group participants jointly reviewed 
and discussed these reports, and progressed from this basis 
to an exchange of experience regarding outcome predictors. 
Final conclusions were drawn collectively following group 
discussions. Three cases with insufficient data were not 
included in this analysis.
Cancer pain with neuropathic 
components
Forty-one cases of cancer pain with neuropathic components 
were reviewed (Figure 1). The mean age of the patients 
was 59.5 ± 13.7 years, with a slightly higher proportion of 
females (56.1%). Mean duration of pain before treatment 
with the lidocaine plaster was 1.77 ± 2.8 years. The majority 
of patients (80.5%) received concomitant pain medication 
during lidocaine plaster treatment. Dose reductions of con-
comitant medication were reported for 64% of the 25 cases 
with available information for this parameter. Physicians 
judged 20 patients (48.8%) as much improved (CGIC = 2) 
and ten patients (24.4%) as very much improved (CGIC = 1) 
following lidocaine plaster treatment. Six patients showed 
minimal improvement and no change was reported for five 
patients.
Hyperalgesia and allodynia were present in 53.7% and 
70.7% of all cases, respectively. Burning pain was reported 
for 26 patients (63.4%) and shooting pain for 21 patients 
(51.2%). The majority of the hyperalgesia patients (72.7%) 
showed at least much improvement following plaster 
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 treatment, but so also did most of the patients without hype-
ralgesia (73.7%). A slight trend towards improved outcome 
was observed for patients with allodynia (75.9% vs 66.7% 
for patients without allodynia) and  for patients with  burning 
pain (76.9% vs 66.7% for patients without burning pain). A 
slight negative trend was observed for patients with shooting 
pain (66.7% vs 80%). Nineteen patients suffered from severe 
allodynia (painful or extremely painful); 15 of those (78.9%) 
were at least much improved.
From these results, neither hyperalgesia, allodynia, 
burning pain, nor shooting pain can be regarded as a clear 
outcome predictor for lidocaine plaster in the treatment of 
cancer pain with neuropathic components. However, the 
participants in one discussion group concluded from their 
clinical experience that hyperalgesia and allodynia (except 
cold allodynia) are potential positive predictors of treat-
ment success with lidocaine plaster. When deciding on 
possible plaster treatment, they would use these as positive 
predictors and widespread pain, anesthesia/numbness, and 
cold allodynia as negative predictors. In contrast, the other 
discussion group regarded allodynia and burning pain as 
potentially helpful but not sufficient, and had varying expe-
riences concerning anesthesia. In their view, the ability of 
the patient to describe and localize the pain area may serve 
as a positive predictor.
In general, this group thought that the case reports 
collected prior to the meeting did not contain enough 
 information about the cause of the neuropathic pain to 
cluster cases and to draw definite conclusions. Information 
regarding a relationship of the experienced neuropathic 
pain to treatment (chemotherapy, radiotherapy, surgery) or 
to the cancer (ie, compression, infiltration) was thus sought 
after the meeting. Physicians kindly provided details, and all 
cases were stratified by relationship to treatment or cancer 
(Tables 1–4).
Pain related to chemotherapy
Pain was considered related to chemotherapy in seven 
patients (Table 1). Four males and three females (age range 
43–68 years, pain duration 1 month–1.67 years) received 
lidocaine plaster treatment for 0.5–2 months as monotherapy 
(three patients) or add-on treatment (four patients). Treatment 
success was reported for all seven patients (CGIC # 2). 
 Complex regional pain syndrome was diagnosed in two 
of these patients and one patient presented with thoracic 
scar pain (considered related to chemotherapy, surgery and 
cancer).
Example cases
1. A 60-year-old male with lung adenocarcinoma whose 
neuropathic, burning pain in his right foot and thora-
cotomy scar was considered related to chemotherapy 
and had been present for 18 months. The average pain 
intensity varied from 4 to 9 on the visual analog scale 
Cancer pain with neuropathic
components n = 41
Concomitant medication to lidocaine plaster: 80.5%
Physicians' impressions
(CGIC)
Very much improved: 10 (24.4%)
Yes: 64% No: 36%
With information about dose reduction: 25 cases (61%)
Much improved: 20 (48.8%) Minimally improved: 6 (14.6%) No change: 5 (12.2%)
Female: 56.1%
Male: 43.9%
Gender
Duration of pain before treatment: 1.77 ± 2.8 years
Figure 1 Forty-one case reports of patients with cancer pain with neuropathic components were reviewed.
Abbreviation: CGIC, Clinical Global Impression of Change.
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Table 4 Case reports for cancer pain with neuropathic components related to cancer (pain was additionally related to radiotherapy 
in two patients, to surgery in two patients, and to chemotherapy and surgery in one patient)
Gender/case 
number
Age Primary diagnosis  
(pain indication/cause of pain)
Localization of pain  
symptoms
Duration of  
pain in years
Hyper- 
algesia
Allodynia/allodynia  
severity rating
Pain intensity  
(0–10)
Pain quality Mono-  
therapy
Plasters  
per day
Duration of plaster  
treatment (months)
CGIC 
score
M  
C10
52 Nociceptive +	neuropathic pain/cancer  
pain/infiltration of the brachial plexus
Neck and arm (right) 4 5–7 Stabbing, burning, shooting,  
dullness, itch, sensory deficit
N NA NA 1
M  
C37
80 Neuropathic pain, lung neoplasia Dorsal 5 3 7 Burning, like water falling N 1 12 1
F  
C40
82 Bone metastases, colon neoplasia Dorsal 10 X 2 8 Burning N 1 18 1
F 
C33
68 Breast adenocarcinoma, bone  
metastasis T11 and L1
Dorsolumbar with  
intercostal irradiation
0.06 X 6 Shooting, like raging  
toothache
N 1/4 daily for 1st few  
days then every 2nd day
0.75 1
M 
C17
71 Neoplastic pain Right hip 0.67 1 7 Burning Y 1 4 2
M  
C34
69 NSCLC right middle lobe Lombar 0.02 X 7 Burning, shooting N 1/2 2 2
M  
C36
69 Bronchogenic cancer (right IIIb →	IV) Scapulalgia ,0.08 X NA Shooting N 1/4 3 2
F  
C15
47 Uterus sarcoma, intra/retroperitoneal filiae Left lower leg 0.25 3 8 Stabbing, burning N 2 2 2
Fa  
C1
54 Meningioma of right cavernous sinus with  
oculomotor failure (III and IV nerve paralysis)  
and loss of visual acuity
Right frontoparietal  
headache (hemicrania)
7 X 2 2–3 Stabbing, burning, shooting N 1 18 2
Mb  
C29
42 Carcinoma left kidney Region of postoperative scar 0.007 X 2 9 Stabbing, burning N 1 1 2
F  
C12
51 Cancer nociceptive + neuropathic (sigmoide) Belly, thigh, leg 0.25 2 7 Stabbing, burning,  
shooting, tightness
N NA 1 2
F  
C14
48 Breast cancer left, pulmonal filiae + bone Left calf due to cancer  
infiltration of sacrum  
and S1 root
0.08 1 7 Burning N 1 .2 2
Mb,c  
C8
68 Planoepithelial carcinoma right lung  
(complete resection and chemo)
Thoracic region (scar) 0.5 1 6 Shooting Y 1 0.5 2
Fb  
C2
70 Liposarcoma of left kidney Left psoas + T12 1 X 2 3–4 Dysesthesia N 2 16 3
F  
C11
46 Cancer pain metastasis/vertebral T4 Thoracic 10 6–7 Stabbing, burning, shooting N 3 4 3
F  
C9
56 Cancer pain nociceptive and neuropathic Cervicalgies, rachialgies,  
cruralgies
2 7 Burning N NA NA 3
F  
C22
89 Metastases in vertebral column Thoracic spine, radiation to  
the anterior thoracic wall
0.5 X 6 Stabbing, shooting, numbness  
in anterior thoracic wall
N 1 1 3
Ma  
C24
53 Lung cancer, right upper lobectomy Right thoracic pain post  
cancer surgery
0.5 X 1 5 Burning, shooting N 3 NA 4
M  
C30
74 Prostate carcinoma, bone metastases,  
stenosis spinalis
Lumbar spine – level L1–L2 0.08 X 1 9 Burning, shooting N 1 0.5 4
F  
C31
55 Bone metastases from breast cancer,  
radiotherapy
Interscapular pain 0.17 X 1 8 Burning N 1 0.4 4
M  
C35
69 Adenocarcinoma, right lung superior lobe Axillar ,0.08 3 7 Shooting N 1/2 0.1 4
Notes: aPain also related to radiotherapy; bpain also related to surgery; cpain also related to chemotherapy. Allodynia severity rating: 0 = no pain or discomfort to touch, 
1 = uncomfortable, but tolerable to touch, 2 = painful, 3 = extremely painful, patient cannot stand touching; duration of pain was converted to years, the term “weeks” was 
set to ,0.08 in the table and to 0.05 for calculation of means.
Abbreviations: CGIC, Clinical Global Impression of Change rating during treatment with 5% lidocaine-medicated plaster: 1 = very much improved, 2 = much improved, 
3 = minimally improved, 4 = no change; F, female; M, male; NA, not available; N, no; NSCLC, non-small-cell lung carcinoma; X, symptom present; Y, yes.
(VAS) following activity but also with breakthrough 
pain. He also presented with hyperalgesia und uncom-
fortable allodynia (severity score 1). Prior unsuccessful 
treatments included pregabalin, carbamazepine, and 
paracetamol. The patient received three lidocaine plasters 
daily  concomitant to gabapentin (600 mg three times a 
day) for 2 months and was rated much improved.
2. A 48-year-old female with ovarian cancer whose 
 stabbing, neuropathic pain in her swollen hands (mainly 
right hand) was considered related to chemotherapy and 
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Table 4 Case reports for cancer pain with neuropathic components related to cancer (pain was additionally related to radiotherapy 
in two patients, to surgery in two patients, and to chemotherapy and surgery in one patient)
Gender/case 
number
Age Primary diagnosis  
(pain indication/cause of pain)
Localization of pain  
symptoms
Duration of  
pain in years
Hyper- 
algesia
Allodynia/allodynia  
severity rating
Pain intensity  
(0–10)
Pain quality Mono-  
therapy
Plasters  
per day
Duration of plaster  
treatment (months)
CGIC 
score
M  
C10
52 Nociceptive +	neuropathic pain/cancer  
pain/infiltration of the brachial plexus
Neck and arm (right) 4 5–7 Stabbing, burning, shooting,  
dullness, itch, sensory deficit
N NA NA 1
M  
C37
80 Neuropathic pain, lung neoplasia Dorsal 5 3 7 Burning, like water falling N 1 12 1
F  
C40
82 Bone metastases, colon neoplasia Dorsal 10 X 2 8 Burning N 1 18 1
F 
C33
68 Breast adenocarcinoma, bone  
metastasis T11 and L1
Dorsolumbar with  
intercostal irradiation
0.06 X 6 Shooting, like raging  
toothache
N 1/4 daily for 1st few  
days then every 2nd day
0.75 1
M 
C17
71 Neoplastic pain Right hip 0.67 1 7 Burning Y 1 4 2
M  
C34
69 NSCLC right middle lobe Lombar 0.02 X 7 Burning, shooting N 1/2 2 2
M  
C36
69 Bronchogenic cancer (right IIIb →	IV) Scapulalgia ,0.08 X NA Shooting N 1/4 3 2
F  
C15
47 Uterus sarcoma, intra/retroperitoneal filiae Left lower leg 0.25 3 8 Stabbing, burning N 2 2 2
Fa  
C1
54 Meningioma of right cavernous sinus with  
oculomotor failure (III and IV nerve paralysis)  
and loss of visual acuity
Right frontoparietal  
headache (hemicrania)
7 X 2 2–3 Stabbing, burning, shooting N 1 18 2
Mb  
C29
42 Carcinoma left kidney Region of postoperative scar 0.007 X 2 9 Stabbing, burning N 1 1 2
F  
C12
51 Cancer nociceptive + neuropathic (sigmoide) Belly, thigh, leg 0.25 2 7 Stabbing, burning,  
shooting, tightness
N NA 1 2
F  
C14
48 Breast cancer left, pulmonal filiae + bone Left calf due to cancer  
infiltration of sacrum  
and S1 root
0.08 1 7 Burning N 1 .2 2
Mb,c  
C8
68 Planoepithelial carcinoma right lung  
(complete resection and chemo)
Thoracic region (scar) 0.5 1 6 Shooting Y 1 0.5 2
Fb  
C2
70 Liposarcoma of left kidney Left psoas + T12 1 X 2 3–4 Dysesthesia N 2 16 3
F  
C11
46 Cancer pain metastasis/vertebral T4 Thoracic 10 6–7 Stabbing, burning, shooting N 3 4 3
F  
C9
56 Cancer pain nociceptive and neuropathic Cervicalgies, rachialgies,  
cruralgies
2 7 Burning N NA NA 3
F  
C22
89 Metastases in vertebral column Thoracic spine, radiation to  
the anterior thoracic wall
0.5 X 6 Stabbing, shooting, numbness  
in anterior thoracic wall
N 1 1 3
Ma  
C24
53 Lung cancer, right upper lobectomy Right thoracic pain post  
cancer surgery
0.5 X 1 5 Burning, shooting N 3 NA 4
M  
C30
74 Prostate carcinoma, bone metastases,  
stenosis spinalis
Lumbar spine – level L1–L2 0.08 X 1 9 Burning, shooting N 1 0.5 4
F  
C31
55 Bone metastases from breast cancer,  
radiotherapy
Interscapular pain 0.17 X 1 8 Burning N 1 0.4 4
M  
C35
69 Adenocarcinoma, right lung superior lobe Axillar ,0.08 3 7 Shooting N 1/2 0.1 4
Notes: aPain also related to radiotherapy; bpain also related to surgery; cpain also related to chemotherapy. Allodynia severity rating: 0 = no pain or discomfort to touch, 
1 = uncomfortable, but tolerable to touch, 2 = painful, 3 = extremely painful, patient cannot stand touching; duration of pain was converted to years, the term “weeks” was 
set to ,0.08 in the table and to 0.05 for calculation of means.
Abbreviations: CGIC, Clinical Global Impression of Change rating during treatment with 5% lidocaine-medicated plaster: 1 = very much improved, 2 = much improved, 
3 = minimally improved, 4 = no change; F, female; M, male; NA, not available; N, no; NSCLC, non-small-cell lung carcinoma; X, symptom present; Y, yes.
had been present for 3 months; she was diagnosed with 
CRPS I 2 months after chemotherapy. She also presented 
with hyperalgesia and painful allodynia (severity score 2) 
and had received 50 µg/hour fentanyl patch as previ-
ous  treatment. The average pain intensity was 7 on the 
numerical rating scale. The patient received two lidocaine 
plasters daily concomitant to amitriptyline (25 mg three 
times a day) for 2 weeks and was rated much improved, 
with no more pain or edemas and improved functionality 
of her hands.
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Pain related to radiotherapy
Table 2 lists the cases of neuropathic pain considered related 
to radiotherapy. Eight of the nine patients (five females/four 
males, age range 42–68 years, pain duration 3 weeks–10 
years) received lidocaine plaster as add-on therapy. Six 
patients were at least much improved by the treatment; 
minimal or no improvement was documented for the other 
three patients. As neuropathic pain was judged to be related 
also to surgery in four patients, to cancer in another two, and 
to chemotherapy in one patient, it is difficult to ascertain the 
role of radiotherapy as a potential outcome predictor in this 
small sample size.
Pain related to surgery
Fifteen cases of cancer pain with neuropathic components 
(eight females/seven males, age range 42–79 years, pain 
duration 10 days–4 years) were considered related to sur-
gery (Table 3). Lidocaine plaster was mainly administered 
as add-on therapy (73.3% of the patients) and resulted in 
at least much improvement for eleven patients (73.3%), 
minimal improvement for three patients, and no change for 
one patient. Concomitant pain medications were reduced in 
eight of the ten cases with available information. Neuropathic 
pain was also related to radiotherapy in four patients, cancer 
in two, and cancer and chemotherapy in one patient. Seven 
(87.5%) of the eight patients in whom neuropathic pain was 
considered to be only related to surgery reported at least 
much improvement and one patient an unchanged  condition. 
For four of these improved patients, dose reductions in con-
comitant pain medications were documented.
Add-on treatment with lidocaine plaster led to much 
improvement in a 60-year-old patient presenting with 
scar pain of 3 years’ duration following mastectomy. 
 Accompanying symptoms were hyperalgesia, extremely 
painful allodynia, and burning and shooting pain. In contrast, 
the only patient in the surgery group showing no change in 
pain condition following lidocaine plaster treatment was also 
a postmastectomy patient. This 67-year-old patient presented 
with painful allodynia, burning and shooting pain but no 
hyperalgesia, and her pain condition was also considered 
related to radiotherapy.
In two of the three cases with minimal improvement, 
spinal nerves were involved (T12 nerve root and L3 radicu-
lar pain). The L3 radicular pain patient showed none of the 
typical neuropathic pain symptoms, such as hyperalgesia, 
allodynia, or burning pain. Thus it might be hypothesized 
that deep and radicular pain might not respond to lidocaine 
plaster treatment.
Pain related to the cancer
Table 4 lists the 21 neuropathic pain cases related to the 
tumor (eleven females/ten males, age range 42–89 years, 
pain duration 10 days–10 years). Only two patients received 
the lidocaine plaster as monotherapy. Concomitant pain 
medications were reduced in eight of 14 cases with available 
information. Pain was also considered to be possibly related 
to radiotherapy (two patients), surgery (two patients), and 
surgery and chemotherapy (one patient). Pain was rated at 
least much improved for 61.9% of the patients; 38.1% showed 
minimal or no improvement. Ten (62.5%) of the 16 patients 
in whom neuropathic pain was considered to be related only 
to the cancer but not to its treatment showed at least much 
improvement.
Example cases
1. Lidocaine plaster treatment was successful in an 80-year-
old male with lung neoplasia who presented with dorsal 
neuropathic pain. Pain duration was 5 years, with an 
average pain intensity of 7 on the numerical rating scale. 
Clinical symptoms included extremely painful allodynia, 
burning pain, and pain “like water falling.” He had previ-
ously been treated with amitriptyline (50 mg/day). One 
daily lidocaine plaster was added to his current medica-
tion of tramadol (2 × 50 mg/day). During the 12 months 
of treatment, tramadol intake could be reduced, and the 
patient was rated very much improved (CGIC = 1).
2. Possible neuropathic pain did not improve with lidocaine 
plaster treatment in a 55-year-old white female with bone 
metastases from breast cancer who had received both 
chemotherapy and radiotherapy over the last 5 years. The 
patient was also diagnosed with depression.  Interscapular 
pain had been present for 2 months, with an average 
 intensity of 8 on the VAS. Hyperalgesia, burning pain, and 
allodynia (severity score = 1) were also documented. Prior 
therapy included oxycodone (2 × 30 mg/day), diclofenac 
(2 × 75 mg/day), and morphine sulfate (2 × 20 mg/day). 
The patient received one daily lidocaine plaster for 12 days 
in addition to a fentanyl patch (50 µg/hour).
Duration of cancer pain was comparable when strati-
fied according to treatment success: patients with at least 
much improvement (CGIC # 2) had a pain duration of 
1.78 ± 2.78 years, and patients with minimal improvements/no 
change (CGIC 3 or 4) had suffered pain for 1.76 ± 2.97 years.
Trigeminal neuropathic pain
Twenty-four case reports (62.5% female) were available 
for review (Figure 2). The mean age of the patients was 
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Trigeminal neuropathic
pain n = 24
Concomitant medication to lidocaine plaster?
Physicians' impressions (CGIC)
Very much improved: 4 (16.7%)
Yes: 79.2% No: 20.8%
With information about dose reduction: 17 cases (70.8%)
Dose reduction: 47.1% No dose reduction: 52.9%
Much improved: 9 (37.5%) Minimally improved: 4 (16.7%) No change: 6 (25%)
Female: 62.5%
Male: 37.5%
Gender
Duration of pain before treatment: 5.3 ± 6.3 years
Minimally worse: 1 (4.2%)
Figure 2 Twenty-four case reports of patients with trigeminal neuropathic pain were available for review.
Abbreviation: CGIC, Clinical Global Impression of Change.
61.6 ± 16.2 years, with a mean duration of pain before treat-
ment with the lidocaine plaster of 5.3 ± 6.3 years. The major-
ity of patients (79.2%) received concomitant pain medication 
during lidocaine plaster treatment. Carbamazepine (currently 
the treatment of choice for trigeminal neuralgia37) or its 
prodrug oxcarbazepine were administered concomitantly 
to six patients. Some patients reported continuous pain, 
and are therefore probably so-called trigeminal neuralgia 
type 2, which has been defined by neurosurgeons as pain 
in which there is prolonged pain 50% of the time.44 Dose 
reductions of concomitant medication were documented 
for eight (47.1%) of the 17 cases with available informa-
tion for this parameter; all were considered at least much 
improved. Half of the patients (54.2%) were rated at least 
much improved by lidocaine plaster treatment, and 16.7% 
minimally improved. There was no change in 25%, and one 
patient was judged as minimally worse. Two of the patients 
with no change reported difficulties with plaster attachment 
to the skin.
Pain was judged to be predominantly extraoral in the 
majority of patients (79.2%) and initiated by triggers in 
87.5%. Half of the patients with predominantly extraoral 
pain (57.9%) were at least much improved by the treat-
ment. The pain was described as continuous for 25% of the 
patients, as continuous with intermittent flares for 45.8%, 
and as intermittent for 29.2%. Of the 17 patients with either 
continuous pain or continuous pain with intermittent flares, 
nine (52.9%) were at least much improved, three (17.7%) 
minimally improved, and five (29.4%) reported no change 
in condition. The seven patients with intermittent pain all 
had a primary diagnosis of trigeminal neuralgia, and six of 
them had received carbamazepine as prior or concomitant 
medication. At least much improvement was observed in 
four patients (57.1%), one improved minimally, one was 
minimally worse, and there was no change in another.
Duration of trigeminal pain was 4.1 ± 5.6 years for 
patients with CGIC # 2 and 6.7 ± 7.0 years with a CGIC $ 3. 
Hyperalgesia and stabbing pain were present in only a few 
patients (four cases with hyperalgesia and six with stabbing 
pain), burning pain was observed in 13 patients (54.2%), 
and shooting pain in twelve patients (50%). All four patients 
with hyperalgesia (100%) were considered at least much 
improved by lidocaine plaster treatment. Treatment out-
come for burning and shooting pain was similar in patients 
who reported the parameter and in patients who did not. At 
least much improvement was documented for 53.8% of the 
patients with burning pain but also for 54.5% of the patients 
without this type of pain. A similar result was obtained for 
shooting pain (46.7% with and 41.7% without). Allodynia 
was present in 20 patients (83.3%); 50% of these patients 
were considered at least much improved following plaster 
treatment. A CGIC of 2 was, however, also reported for three 
of the four patients without allodynia. Eleven patients suf-
fered from severe allodynia (painful or extremely painful); 
seven of them (63.6%) were at least much improved, two 
minimally, and there was no change in two other patients. 
Of the nine patients with mild allodynia, three had a CGIC 
of 2 and six had a CGIC $ 3.
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Although neither predominantly extraoral pain nor con-
tinuous pain could be regarded as positive outcome predictors 
according to the case reports, the participating physicians con-
sidered both parameters as possible candidates based on their 
clinical experience. They also suggested PHN as a cause of 
trigeminal neuropathic pain and type 2 trigeminal neuralgia, ie, 
with burning pain and allodynia, and traumatic and postsurgi-
cal neuropathy as positive predictors. Predominantly intraoral 
pain was considered as a negative-outcome predictor.
All cases were further stratified according to informa-
tion about the development of trigeminal neuropathic pain 
(Table 5).
Idiopathic trigeminal neuropathic pain
Trigeminal neuropathic pain was considered idiopathic in 
nine patients: six male and three female patients (age range 
29–82 years, pain duration 35 days–20 years) with pre-
dominantly extraoral pain (77.8%) received lidocaine plaster 
treatment mainly as add-on treatment. Primary diagnosis was 
trigeminal neuralgia, which was considered atypical in one 
case. Six of the patients (66.7%) were considered at least 
much improved; there was no change in two patients, and 
one was considered minimally worse.
Example cases
1. Lidocaine plaster treatment was successful in a 53-year-
old male patient who reported intermittent, predominantly 
extraoral stabbing pain for the right side of his face. 
The pain had been present for 3 years, with an average 
pain intensity of 5 on the VAS. He also presented with 
hyperalgesia and painful allodynia. Previous medica-
tions included carbamazepine and pregabalin. After 
28 days of treatment with half a lidocaine plaster as 
monotherapy, the patient’s condition was judged very 
much improved.
2. In contrast, 2 months of daily treatment with half a lido-
caine plaster in addition to 900 mg carbamazepine twice 
a day did not change stabbing, shooting, intermittent, pre-
dominantly extraoral pain in the left cheek/mandibular of 
a 75-year-old male patient. His pain had been present for 
5 years, with an average pain intensity of 8 on the VAS.
Trigeminal neuropathic pain following 
surgery for trigeminal neuralgia
Six patients suffered from trigeminal neuropathic pain 
related to surgery for trigeminal neuralgia (Table 5; five 
females, one male; age range 35–75 years, pain duration 
2–25 years). Treatment with lidocaine plaster varied from 
0.17 to 9 months; two patients received the plaster as 
monotherapy. One patient was rated very much improved, 
three were minimally improved, and there was no change in 
another two patients.
Example cases
Treatment was successful in a 53-year-old female patient with 
atypical trigeminal neuralgia who presented with continuous 
neuropathic pain (intra- and extraoral) at the right trigeminal 
nerve divisions 2 and 3. Pain duration was 12 years, with 
an average pain intensity of 10 on the Brief Pain Inventory. 
Clinical symptoms included painful allodynia, and shooting 
and sharp pain. She had previously received carbamazepine, 
but cannot tolerate systemic medications. Nightly lidocaine 
plaster treatment (half a plaster) as long-term monotherapy 
(9 months) very much improved her pain and general status 
(sleeps well and depression has lifted). In contrast, there was 
no change following 1 month of lidocaine plaster treatment as 
add-on therapy to oxcarbazepine 450 mg daily in an 82-year-
old female patient also presenting with atypical trigeminal 
neuralgia. Her extraoral, continuous pain with intermittent 
flare-ups of the left ophthalmic, maxillary, and mandibular 
trigeminal branches had been present for 5 years and was 
considered to have a possible neuropathic component. Burn-
ing pain, aching dull pain, acute sharp pain, and allodynia 
(severity score = 1) were documented. Previous medica-
tions included morphine, fentanyl patches,  paracetamol/
codeine combination and gabapentin; she also received 
 radiofrequency thermocoagulation therapy. Her diagnosis 
was later changed to short unilateral neuralgiform pain with 
conjunctival tearing, and she responded to lamotrigine (listed 
under trigeminal neuralgia in Table 5).
Trigeminal neuropathic pain related  
to trauma
Trigeminal neuropathic pain was considered related to trauma 
in four patients (Table 5; three female, one male; age range 
44–65 years, pain duration 1.5–4 years). Three patients had 
predominantly extraoral pain. All patients reported con-
tinuous pain (three also with intermittent flares), and three 
patients had allodynia. Add-on treatment with the lidocaine 
plaster for 2 weeks to 7 months much improved pain in three 
cases; there was no change in the one patient receiving the 
plaster for only 2 weeks.
Trigeminal neuropathic pain following PHN
PHN was considered the cause of trigeminal  neuropathic 
pain in four patients (three female, one male; age 
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range 45–78 years, pain duration 0.25–2.5 years; Table 5). 
All reported continuous pain (three with intermittent flares), 
which was predominantly extraoral in three cases. A neu-
ropathic component to the pain was considered definite 
for all four cases. All patients reported burning pain; three 
patients had allodynia. Three patients received daily plasters 
(quarter or half) as additional treatment; one was treated 
intermittently with the plaster as monotherapy. Treatment 
much improved pain in the three patients with predominantly 
extraoral pain (including the patient on monotherapy) and 
minimally in the fourth patient with intra- and extraoral 
pain who had only been on lidocaine plaster treatment for 
a few weeks.
Practical experiences with the 5% lidocaine-medicated 
plaster were in general positive due to its convenience. 
 Nevertheless, some patients using the lidocaine plaster 
reported difficulties (numbers in brackets refer to case num-
bers in Table 5). A female patient (T18) with both intraoral 
and extraoral pain (trigeminal neuralgia type 2) considered 
the plaster as not very helpful as her main trigger was eat-
ing; she also found the plaster too painful to put on and too 
fiddly to handle and only used it for 1 week. One patient 
found the plaster unpleasant to wear and painful to remove 
(T3). One patient had difficulties in cutting it into smaller 
pieces and perceived it as conspicuous when wearing it on 
the face, although the patient would wear it when going out 
in the cold (T11). Two patients found it difficult to attach 
to the face (T12 and T16), and one difficult to readjust 
to the return of pain after removal of plaster (T19). One 
patient (T8) reported some skin irritation. One patient (T10) 
reported gaining more benefit from lidocaine plaster after a 
few weeks of use, which corresponds to a lidocaine plaster 
study in PHN where a trial period of 2–4 weeks is considered 
necessary in order to decide whether or not a patient will 
respond to the treatment.11 Add-on treatment with lidocaine 
plaster improved sleep in eight patients (T10, T11, T13, T14, 
T15, T17, T19, and T22) whose pain was often provoked by 
contact with bedclothes. Regular use of lidocaine plaster in 
one patient who could not tolerate any systemic medications 
(T17) completely resolved her depression as measured on 
the hospital anxiety and depression scale pre- and postuse 
of the plaster.
Discussion
Evaluation of potential predictors for treatment success 
with the lidocaine plaster included a number of different 
parameters specific to the nature of the disorder. Results are 
therefore discussed separately for each indication; a summary 
of the overall experience with the plaster is given at the end 
of the Discussion section.
Cancer pain with neuropathic 
components
Group discussions and case-report analysis identified some 
parameters as positive- or negative-outcome predictors 
for the treatment of neuropathic cancer pain with the 5% 
lidocaine-medicated plaster, but were not conclusive for 
several others (Table 6). Not only typical neuropathic pain 
features, such as hyperalgesia, allodynia, and burning pain, 
had to be evaluated but also the cause of the neuropathic 
pain (related to cancer treatment or to the cancer itself) had 
to be taken into account. Interpretations were difficult when 
multiple causes for neuropathic pain were present.
There had been general agreement in the last three 
pain specialist meetings that allodynia is a highly probable 
positive predictor for the indications DPN, CRPS, chronic 
low back pain with neuropathic components, and chronic 
neuropathic pain after surgical and nonsurgical trauma.24 
Furthermore, marked improvements of allodynia with the 
lidocaine plaster had been noted in several randomized, 
controlled studies,9,10,12 and add-on therapy was more often 
successful in patients with allodynia than in patients without.47 
However, the lidocaine plaster was comparably efficacious 
in patients with painful diabetic polyneuropathy presenting 
with or without allodynia.48 From their clinical experience, 
some of the participants in this meeting considered allodynia 
as a positive outcome predictor for neuropathic cancer pain, 
while others regarded this parameter as potentially helpful 
but not  sufficient. The analysis of the case reports contributed 
showed that although there was a slight trend towards a posi-
tive outcome in the presence of allodynia or burning pain, and 
shooting pain had a slightly worse predictive value, 73% of all 
patients showed much or very much improvement, regardless 
of any of these parameters being present or not. A similar 
result was obtained for hyperalgesia. From these results, the 
presence of allodynia, hyperalgesia, or pain quality does not 
provide a clear indication of treatment success for neuropathic 
cancer pain. A possible reason for our findings could be the 
high incidence of mixed pain conditions in cancer pain.26,27
Chronic postsurgical neuropathic pain is often severely 
debilitating, affecting the economic and emotional well-being 
of the patients; incidences vary according to type of surgery.49 
Lidocaine plaster treatment was almost always successful in 
cancer patients whose pain was related to surgery. This find-
ing did not come as a surprise, since it is in agreement with 
an open-label study by Hans et al15 in patients suffering from 
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Table 5 Case reports for trigeminal pain 
Gender /
case number
Age Primary diagnosis (pain indication/cause  
of pain/type of pain)
Localization of pain symptoms/
predominantly intra- or extraoral
Duration of  
pain in years
Hyper- 
algesia
Allodynia/allodynia  
severity rating
Pain intensity  
(0–10)
Characteristics of pain Mono-  
therapy
Plasters  
per day
Duration of plaster  
treatment (months)
CGIC  
score
Trigeminal neuralgia
M  
T4
76 Trigeminal neuralgia  
Intermittent pain
Left V1  
Extraoral
0.19 X 2 9 Stabbing N 1/8 1.17 1
Ma  
T26
82 Trigeminal neuralgia type 2  
Continuous pain
Right V1,2,3  
Extraoral
20 X 3 8–10 Burning N 1/2 0.93 1
M  
T27
53 Trigeminal neuralgia  
Intermittent pain
Right V  
Extraoral
3 X 2 5 Stabbing Y 1/2 0.93 1
F  
T2
62 Trigeminal neuralgia type 2  
Continuous pain with intermittent flares
Left  
Extraoral
3 7 Burning, shooting N 1/2 NA 2
F  
T6
29 Trigeminal neuralgia  
Intermittent pain
V2  
Extraoral
0.5 X 1 7 Shooting N 1/2 0.75 2
Ma  
T24
35 Trigeminal neuralgia  
Intermittent pain
Left V2  
Extraoral
3 2 8 Shooting N 1/4 3 2
F  
T18
62 Trigeminal neuralgia type 2  
Continuous pain with intermittent flares
Right V2,3  
Extraoral, mainly intraoral
14 2 8 Stabbing, shooting,  
aching
N 1/2 0.25 4
M  
T1
75 Trigeminal neuralgia  
Intermittent pain
Left V2,3  
Extraoral
5 8 Stabbing, shooting N 1/2 2 4
M  
T3
80 Trigeminal neuralgia  
Intermittent pain
Left V2,3 $5 1 9 Stabbing, shooting Y 1/2, not daily ,0.03 5
F  
T23
82 Neuralgia SUNCT  
Continuous pain with intermittent flares
Left V1,2,3  
Extraoral
5 1 7 Burning, sharp,  
aching, dull
N 1 1 4
Trigeminal neuropathic pain following surgery for trigeminal neuralgia
F  
T17
53 Neuropathic pain  
Continuous pain
Right V2,3  
Intra- and extraoral
12 2 10 Shooting, sharp Y 1/2 9 1
F  
T21
49 Neuropathic pain  
Continuous pain
Right V2,3  
Extraoral
2 2 8 Burning N 1 weekly 1 3
F  
T11
64 Bilateral neuropathic pain  
Intermittent pain
Right V2,3  
Extraoral
3 1 8 Shooting, hot, pricking N 1/2 0.17 3, sleep 
improved
Fa  
T7
35 Neuropathic pain  
Continuous pain with intermittent flares
V2,3  
Extraoral
2 2 8 Burning, shooting N 1/2 0.7 3
F  
T12
72 Dysesthesia  
Continuous pain with intermittent flares
Left V3  
Extraoral
7 2 8 Heavy, gripping N 1/2 0.25 4
M  
T16
75 Dysesthesia  
Continuous pain
Left V2,3  
Extraoral
25 1 8 Burning, soreness,  
nagging, numbness
Y 1 3 4
Trigeminal neuropathic pain following trauma
F  
T13
50 Trigeminal posttraumatic neuropathic pain  
Continuous pain
Left V2  
Extraoral
1.5 2 9 Burning, tingling,  
pricking
N 1/2 4 2
F  
T22
65 Trigeminal neuropathic pain  
Continuous pain with intermittent flares
Left V1,2,3  
Extraoral
3 1 8 Burning, shooting, throbbing,  
drilling, heavy, piercing
N 1 every  
2nd day
7 2 sleeps 
better
F  
T15
63 Neuropathic pain after extractions  
Continuous pain with intermittent flares
Right V3  
Intraoral 
Extraoral
3 7 Shooting, cutting,  
aching, throbbing
N 1/2 3 2
M  
T20
44 Trigeminal neuropathic pain after dental extractions  
Continuous pain with intermittent flares
Right V1,2,3  
Extraoral
4 1 Burning, sharp, dull N 1 every  
2nd day
0.5 4
Trigeminal neuropathic pain following postherpetic neuralgia
F  
T10
45 Postherpetic neuralgia  
Continuous pain with intermittent flares
Right V1  
Extraoral
2.5 1 10 Stabbing, searing, burning,  
shooting, dull
N 1/2 3 2
M  
T8
78 Postherpetic neuralgia  
Continuous pain with intermittent flares
Right V1  
Extraoral
0.25 2 7 Burning N 1/4 3 2
F  
T14
74 Postherpetic neuralgia  
Continuous pain
Left V1  
Extraoral
1.67 4 Burning, itchy, hot,  
numb, tingling
Y Intermittent 4 2
F  
T19
76 Postherpetic neuralgia pain and burning mouth syndrome  
Continuous pain with intermittent flares
Right V2  
Intra- and extraoral
2 1 9 Burning, drilling N 1/2 Few weeks 3
Notes: Pain was initiated by triggers if not otherwise stated. ano triggers. Allodynia severity rating: 0 = no pain or discomfort to touch, 1 = uncomfortable, but tolerable to 
touch, 2 = painful, 3 = extremely painful, patient cannot stand touching; duration of pain was converted to years, term “many years” was set to $5 years in the table and to 
5 years for calculation of means.
Abbreviations: CGIC, Clinical Global Impression of Change rating during treatment with 5% lidocaine-medicated plaster: 1 = very much improved, 2 = much improved, 
3 = minimally improved, 4 = no change, 5 = minimally worse; F, female; M, male; NA, not available; N, no; SUNCT, short unilateral neuralgiform pain with conjunctival tearing; 
V1, ophthalmic; V2, maxillary; V3, mandibular; X, symptom present; Y, yes.
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Table 5 Case reports for trigeminal pain 
Gender /
case number
Age Primary diagnosis (pain indication/cause  
of pain/type of pain)
Localization of pain symptoms/
predominantly intra- or extraoral
Duration of  
pain in years
Hyper- 
algesia
Allodynia/allodynia  
severity rating
Pain intensity  
(0–10)
Characteristics of pain Mono-  
therapy
Plasters  
per day
Duration of plaster  
treatment (months)
CGIC  
score
Trigeminal neuralgia
M  
T4
76 Trigeminal neuralgia  
Intermittent pain
Left V1  
Extraoral
0.19 X 2 9 Stabbing N 1/8 1.17 1
Ma  
T26
82 Trigeminal neuralgia type 2  
Continuous pain
Right V1,2,3  
Extraoral
20 X 3 8–10 Burning N 1/2 0.93 1
M  
T27
53 Trigeminal neuralgia  
Intermittent pain
Right V  
Extraoral
3 X 2 5 Stabbing Y 1/2 0.93 1
F  
T2
62 Trigeminal neuralgia type 2  
Continuous pain with intermittent flares
Left  
Extraoral
3 7 Burning, shooting N 1/2 NA 2
F  
T6
29 Trigeminal neuralgia  
Intermittent pain
V2  
Extraoral
0.5 X 1 7 Shooting N 1/2 0.75 2
Ma  
T24
35 Trigeminal neuralgia  
Intermittent pain
Left V2  
Extraoral
3 2 8 Shooting N 1/4 3 2
F  
T18
62 Trigeminal neuralgia type 2  
Continuous pain with intermittent flares
Right V2,3  
Extraoral, mainly intraoral
14 2 8 Stabbing, shooting,  
aching
N 1/2 0.25 4
M  
T1
75 Trigeminal neuralgia  
Intermittent pain
Left V2,3  
Extraoral
5 8 Stabbing, shooting N 1/2 2 4
M  
T3
80 Trigeminal neuralgia  
Intermittent pain
Left V2,3 $5 1 9 Stabbing, shooting Y 1/2, not daily ,0.03 5
F  
T23
82 Neuralgia SUNCT  
Continuous pain with intermittent flares
Left V1,2,3  
Extraoral
5 1 7 Burning, sharp,  
aching, dull
N 1 1 4
Trigeminal neuropathic pain following surgery for trigeminal neuralgia
F  
T17
53 Neuropathic pain  
Continuous pain
Right V2,3  
Intra- and extraoral
12 2 10 Shooting, sharp Y 1/2 9 1
F  
T21
49 Neuropathic pain  
Continuous pain
Right V2,3  
Extraoral
2 2 8 Burning N 1 weekly 1 3
F  
T11
64 Bilateral neuropathic pain  
Intermittent pain
Right V2,3  
Extraoral
3 1 8 Shooting, hot, pricking N 1/2 0.17 3, sleep 
improved
Fa  
T7
35 Neuropathic pain  
Continuous pain with intermittent flares
V2,3  
Extraoral
2 2 8 Burning, shooting N 1/2 0.7 3
F  
T12
72 Dysesthesia  
Continuous pain with intermittent flares
Left V3  
Extraoral
7 2 8 Heavy, gripping N 1/2 0.25 4
M  
T16
75 Dysesthesia  
Continuous pain
Left V2,3  
Extraoral
25 1 8 Burning, soreness,  
nagging, numbness
Y 1 3 4
Trigeminal neuropathic pain following trauma
F  
T13
50 Trigeminal posttraumatic neuropathic pain  
Continuous pain
Left V2  
Extraoral
1.5 2 9 Burning, tingling,  
pricking
N 1/2 4 2
F  
T22
65 Trigeminal neuropathic pain  
Continuous pain with intermittent flares
Left V1,2,3  
Extraoral
3 1 8 Burning, shooting, throbbing,  
drilling, heavy, piercing
N 1 every  
2nd day
7 2 sleeps 
better
F  
T15
63 Neuropathic pain after extractions  
Continuous pain with intermittent flares
Right V3  
Intraoral 
Extraoral
3 7 Shooting, cutting,  
aching, throbbing
N 1/2 3 2
M  
T20
44 Trigeminal neuropathic pain after dental extractions  
Continuous pain with intermittent flares
Right V1,2,3  
Extraoral
4 1 Burning, sharp, dull N 1 every  
2nd day
0.5 4
Trigeminal neuropathic pain following postherpetic neuralgia
F  
T10
45 Postherpetic neuralgia  
Continuous pain with intermittent flares
Right V1  
Extraoral
2.5 1 10 Stabbing, searing, burning,  
shooting, dull
N 1/2 3 2
M  
T8
78 Postherpetic neuralgia  
Continuous pain with intermittent flares
Right V1  
Extraoral
0.25 2 7 Burning N 1/4 3 2
F  
T14
74 Postherpetic neuralgia  
Continuous pain
Left V1  
Extraoral
1.67 4 Burning, itchy, hot,  
numb, tingling
Y Intermittent 4 2
F  
T19
76 Postherpetic neuralgia pain and burning mouth syndrome  
Continuous pain with intermittent flares
Right V2  
Intra- and extraoral
2 1 9 Burning, drilling N 1/2 Few weeks 3
Notes: Pain was initiated by triggers if not otherwise stated. ano triggers. Allodynia severity rating: 0 = no pain or discomfort to touch, 1 = uncomfortable, but tolerable to 
touch, 2 = painful, 3 = extremely painful, patient cannot stand touching; duration of pain was converted to years, term “many years” was set to $5 years in the table and to 
5 years for calculation of means.
Abbreviations: CGIC, Clinical Global Impression of Change rating during treatment with 5% lidocaine-medicated plaster: 1 = very much improved, 2 = much improved, 
3 = minimally improved, 4 = no change, 5 = minimally worse; F, female; M, male; NA, not available; N, no; SUNCT, short unilateral neuralgiform pain with conjunctival tearing; 
V1, ophthalmic; V2, maxillary; V3, mandibular; X, symptom present; Y, yes.
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neuropathic scar pain and a previous case series analyzed for 
the 2009 pain-specialist meeting.24
Neuropathy is a common adverse effect of chemotherapy, 
with tingling, numbness, impaired sensory function, and 
pain the most common symptoms.50 All seven patients with 
neuropathic pain considered related to chemotherapy were 
successfully treated with the lidocaine plaster. This result is 
encouraging, as chemotherapy-induced peripheral neuropa-
thy has so far been relatively refractory to existing first-line 
treatments for neuropathic pain.8 In two of the patients, the 
pain was diagnosed as CPRS, which has been treated suc-
cessfully with the plaster in previous cases18,51,52 and was 
given a high probability of treatment success.24
Duration of neuropathic pain and pain directly related 
to the cancer did not have any predictive value. A possible 
predictor role for radiotherapy was difficult to ascertain 
because the neuropathic pain of most of these patients was 
also related to other causes.
A number of case reports did not include data for 
dose reductions of concomitant pain medications; the 
available data indicate that treatment with the lidocaine 
plaster allowed a dose reduction in at least 50% of the 
patients using the plaster as adjunct treatment. This find-
ing corresponds to results of other investigations with the 
lidocaine plaster reporting marked reductions in systemic 
medication.11,53 A reduction of concomitant systemic pain 
medications while maintaining efficient pain relief with 
the lidocaine plaster might lower the risk of systemic 
side effects, such as nausea, sedation, dizziness, and 
constipation, and could thus improve quality of life and 
patient  compliance. In  addition, the low systemic exposure 
after plaster application54 might also reduce the risk of phar-
macokinetic interactions with concomitant medications in 
this likely polymedicated patient population.
Trigeminal neuropathic pain
Lidocaine plaster treatment was successful (at least much 
improved) in approximately every second patient (54%) 
described in the submitted case reports. Given the small 
number of case reports (n = 24) investigated for this indica-
tion, it is therefore difficult to judge the predictive value of 
different parameters. Furthermore, the site of the pain (eg, 
face, intraoral) and the sometimes very small size of the pain-
ful area can pose technical problems with plaster application 
and attachment in this indication. Owing to the high muscle 
activity and movement in the face, plaster attachment can 
be difficult, especially if smaller plaster pieces are used. Its 
appearance might also limit its use during the daytime, when 
many patients get evoked pain from triggers.
Although there was no clear indication from the case 
report analysis, participants considered continuous pain and 
predominantly extraoral pain as possible positive outcome 
predictors and predominantly intraoral pain as a possible 
negative predictor.
Signs and symptoms of different types of facial neuro-
pathic pain can overlap considerably.42,43 In 14 of the included 
case reports, trigeminal neuralgia was stated as the primary 
diagnosis/cause of pain. Some of these patients might have 
presented with neuropathic pain caused by trigeminal neu-
ralgia instead of trigeminal neuropathic pain, in which case 
Table 6 Probability of treatment success with 5% lidocaine-medicated plaster
Probability Potential predictors Indication
Long-terma Short-termb
High Localized pain
Superficial pain
Allodynia
Postherpetic neuralgia
Diabetic polyneuropathy
Chronic postsurgical pain
Complex regional pain syndrome
Post herpes zoster
Scar pain (postsurgery)
Medium Hyperalgesia
Burning
Stabbing
Shooting 
Numeric rating scale score
Low back pain (chronic)
Cancer pain with neuropathic  
components
Trigeminal neuropathic pain
Low back pain
Carpal tunnel syndrome
Low Deep pain
Numbness
Radiating pain
Radicular pain
Heavy sweating
Pain site distant from nerve damage
Chronic widespread
Central pain Fibromyalgia
Arthrosis
Gout
Phantom limb pain
Muscular pain
Notes: aDuration months to years; bduration days to weeks.
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the lidocaine plaster would not have been the most appropri-
ate treatment. Facial herpes zoster infection and subsequent 
PHN is not uncommon and appears to affect women more 
frequently than men.55 In 17% of the current case series, PHN 
was considered the cause of trigeminal neuropathic pain, and 
three of the four patients were in fact women; however, the 
number of cases is too small to draw any conclusions. All 
PHN cases with predominately extraoral pain showed much 
improvement, which corresponds to the overall observation 
that extraoral pain might be a possible positive outcome 
predictor, in particular if caused by PHN.
Misdiagnosis can lead to a long trial-and-error period 
to find the right medication and can substantially impair 
the quality of life of the patient. As an example, we refer 
the reader to the case of a patient with short unilateral 
neuralgiform pain with conjunctival tearing that had been 
misdiagnosed as atypical trigeminal neuralgia for 5 years, 
as previously described. The implications of both misdi-
agnosis and potential mismanagement are discussed in a 
recent review.40
In contrast to cancer pain with neuropathic components, 
there was no predictive value for the parameter “pain related 
to surgery” for trigeminal neuropathic pain. It should be 
noted that the term “pain related to surgery” has a different 
meaning in the two indications. In cancer patients, it refers 
to localized scar pain following surgery; in patients with 
trigeminal neuropathic pain, however, procedures such as 
dental or trigeminal surgery might trigger a nerve response 
not localized at the site of the wound.
Pain quality, mild allodynia, and cold allodynia were 
considered of no predictive value, but the case analysis 
showed a positive outcome in patients with severe allodynia, 
hyperalgesia, PHN as the cause of neuropathic pain, and 
trauma.
Two patients in the current case series (T4 and T6) 
showed an excellent response to add-on treatment with lido-
caine plaster, but the duration of the pain was only 9 weeks 
and 6 months, respectively. These patients could have been 
going into remission, which is common after a first attack 
of trigeminal neuralgia.
Trigeminal neuropathic pain patients used the lidocaine 
plaster mainly at night when allodynia interfered with sleep, 
and one-third of the patients did in fact report improved sleep. 
The recording of sleep patterns pre- and postuse could be 
considered a future study objective to investigate whether this 
might be a useful outcome parameter. In general, however, 
it would be important to consider lidocaine plaster in those 
patients who are on other drugs that could interfere with 
systemic analgesic medications; this is for instance highly 
likely in elderly patients.
It might be generally difficult to justify the continuous 
application of lidocaine plaster in trigeminal neuropathic pain 
patients with episodic pain and in patients with predominately 
evoked pain due to light touch triggers who may find the 
plaster difficult to apply. Patients with spontaneous, more 
continuous pain may be more willing to try.
Many of the patients described in these case reports used 
lidocaine plaster intermittently and possibly not for long 
enough to have an effect, since data from controlled studies 
in PHN and DPN suggest a more pronounced effect after 
2–4 weeks.56 Thus, administration should be regular and for 
at least a few weeks.
Successful treatment of different neuropathic pain states 
with the lidocaine plaster has led to the suggestion of a com-
mon symptomatology with common predictors of treatment 
success. A ranking table proposing treatment success with 
high, medium, or low probability for a combination of a pre-
dictor with an indication was therefore created and updated in 
each of the four pain-specialist meetings based on published 
evidence, submitted case reports, and the experience of the 
participants (Table 6).
Overall, there is a medium probability of treatment 
success for cancer pain with neuropathic components, 
which seems to be independent of the typical neuropathic 
features hyperalgesia, allodynia, and pain qualities such as 
burning and shooting pain. Treatment benefits, however, 
seem to be probable if a relationship of the pain to surgery 
or  chemotherapy can be established and if chemotherapy-
induced neuropathic pain is a localized pain permitting 
the use of a plaster. The participants of the meeting did not 
think that the term “cancer pain” represents a valid pain 
classification. Pain in a cancer patient may be caused by the 
tumor itself, may be treatment-related, may be both, or may 
in fact be tumor-independent. The treating physician’s utmost 
goal must be to relieve this pain as quickly as possible and 
therefore avoid long trial-and-error periods by careful diag-
nostics. In any patient presenting with cancer pain, it needs 
to be established, if possible, whether the pain is likely of 
nociceptive or neuropathic nature. Given the results of our 
case analysis, a trial period with lidocaine plaster (possibly as 
add-on with subsequent attempts to reduce other medications) 
is worth pursuing if the pain is considered to be localized 
neuropathic pain and also likely to be caused by surgery or 
chemotherapy. Despite the encouraging observation that two-
thirds of the radiotherapy patients experienced pronounced 
pain relief under treatment with the plaster, we cannot draw 
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any conclusions concerning radiotherapy-related neuropathic 
pain from this case series. There were too many confounding 
factors, ie, other or additional possible causes for the neu-
ropathic pain. Further study of this condition with a larger 
sample size is clearly warranted.
The available data did not permit identification of any 
predictors suggestive of treatment success or treatment failure 
with lidocaine plaster for the indication trigeminal neuro-
pathic pain. However, since more than half of the patients 
showed a positive response to plaster treatment, the plaster 
may be a valuable add-on option for patients insufficiently 
treated with their present medication, and it may also be con-
sidered as monotherapy in patients who are unable to tolerate 
systemic medication. These assumptions need, however, to 
be investigated in future studies.
Limitations
It should be noted that the case reports submitted for 
 discussion at the meeting were selected by the participants. 
The selection is likely biased and thus is not necessarily 
representative of the entire patient population treated for 
neuropathic cancer pain or trigeminal neuropathic pain. The 
small sample size of the different subgroups also needs to 
be  acknowledged. Careful sensory testing with clear indica-
tions of the type of sensory deficit experienced, as suggested 
by Maier et al57 was not carried out in the small sample, 
and this would need to be done in future larger studies, 
as it may provide clear predictors for outcome. However, 
the reports permit a first evaluation of potential benefits of 
lidocaine plaster treatment for these conditions, and thus 
support conducting large, well-designed multicenter studies.
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